25,210 Shares of Boston Scientific Corporation $BSX Purchased by Murphy Pohlad Asset Management LLC

Murphy Pohlad Asset Management LLC bought a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 25,210 shares of the medical equipment provider’s stock, valued at approximately $1,100,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BSX. GraniteShares Advisors LLC increased its stake in shares of Boston Scientific by 1.5% during the 1st quarter. GraniteShares Advisors LLC now owns 13,599 shares of the medical equipment provider’s stock valued at $853,000 after acquiring an additional 195 shares during the last quarter. Avantax Planning Partners Inc. grew its holdings in Boston Scientific by 4.0% in the first quarter. Avantax Planning Partners Inc. now owns 5,242 shares of the medical equipment provider’s stock valued at $329,000 after purchasing an additional 201 shares during the period. WPG Advisers LLC increased its position in Boston Scientific by 11.9% during the first quarter. WPG Advisers LLC now owns 1,916 shares of the medical equipment provider’s stock worth $120,000 after purchasing an additional 203 shares during the last quarter. Natural Investments LLC increased its position in Boston Scientific by 1.3% during the second quarter. Natural Investments LLC now owns 16,067 shares of the medical equipment provider’s stock worth $685,000 after purchasing an additional 206 shares during the last quarter. Finally, 180 Wealth Advisors LLC raised its stake in Boston Scientific by 3.6% during the first quarter. 180 Wealth Advisors LLC now owns 6,468 shares of the medical equipment provider’s stock worth $406,000 after purchasing an additional 223 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Price Performance

Shares of BSX traded down $0.34 during midday trading on Friday, reaching $45.67. The stock had a trading volume of 8,771,849 shares, compared to its average volume of 15,836,739. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The company has a market capitalization of $66.19 billion, a P/E ratio of 18.49, a P/E/G ratio of 1.11 and a beta of 0.58. The firm’s 50 day moving average price is $45.46 and its 200-day moving average price is $49.16. Boston Scientific Corporation has a 52 week low of $41.38 and a 52 week high of $105.65.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company’s revenue was up 7.5% on a year-over-year basis. During the same quarter last year, the business posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, analysts forecast that Boston Scientific Corporation will post 3.24 earnings per share for the current fiscal year.

Analysts Set New Price Targets

BSX has been the topic of a number of recent research reports. Evercore reduced their target price on shares of Boston Scientific from $65.00 to $52.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 7th. TD Cowen reaffirmed a “buy” rating on shares of Boston Scientific in a report on Tuesday. Canaccord Genuity Group dropped their price target on shares of Boston Scientific from $70.00 to $66.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Argus reiterated a “hold” rating on shares of Boston Scientific in a report on Friday, July 31st. Finally, Jefferies Financial Group cut their price objective on shares of Boston Scientific from $67.00 to $60.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $68.23.

Insider Activity

In related news, Director David C. Habiger acquired 2,100 shares of the stock in a transaction dated Wednesday, August 5th. The shares were acquired at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the purchase, the director owned 17,160 shares in the company, valued at approximately $816,644.40. The trade was a 13.94% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Edward J. Ludwig acquired 5,000 shares of the business’s stock in a transaction dated Friday, July 31st. The shares were bought at an average cost of $45.48 per share, with a total value of $227,400.00. Following the transaction, the director directly owned 30,359 shares of the company’s stock, valued at $1,380,727.32. The trade was a 19.72% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have purchased 194,522 shares of company stock valued at $9,385,210. Insiders own 0.34% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.